Novozymes to use Benson Hill’s Cpf1 and Cms1 genome editing portfolio across its business segments

Benson Hill Biosystems, a crop improvement company unlocking the natural diversity of plants, and Novozymes, a leader in enzymes and microbial technologies, today announced that they have entered into a research and commercial license agreement for use of Benson Hill’s editing portfolio across Novozymes’ business segments.

Enzymes and microbes offer a biological solution to improve the efficiency and sustainability of products across many industries – from agriculture and food production to energy and household care. Through this partnership, Novozymes will access Benson Hill’s technology platform to leverage the natural diversity of microorganisms with greater speed and precision than previously possible, improving functionality across many applications.

“Novozymes works with innovative customers across the globe to help them produce more from less, make their products stand out and reduce costs,” said Claus Crone Fuglsang, CSO and Senior Vice President, Research & Technology, Novozymes. “Benson Hill’s robust portfolio of gene editing nucleases and collaborative approach to empowering innovation aligns with our mission to leverage biological innovations and create new opportunities for our customers.”

Benson Hill empowers organizations of any size across the agri-food value chain to benefit from the most advanced tools in genomic innovation, including the largest portfolio of Cpf1 and Cms1 nucleases in industry. “This technology enables the biotech industry to access the most advanced tools to further leverage nature’s diversity for social and environment benefit,” said Matt Crisp, CEO of Benson Hill Biosystems.